Letybo

Letybo and Jeuveau are both frown-line injections, and they compete mostly on price. Both are botulinum toxin type A, given as 20 units in a few small shots. Jeuveau was tested head to head against Botox and did about as well. Letybo was tested against a placebo, and nobody has compared the two brands to each other.
| The difference | Letybo | Jeuveau |
|---|---|---|
| What it is | Botulinum toxin type A | Botulinum toxin type A |
| Cost | Entered as the lower-cost option | Built on being the value option |

Botulinum toxin type A In use in the US since 2019.
Side by side
Letybo
Botulinum toxin type A
The newer of the two in the US. It arrived in 2025.
Jeuveau
Botulinum toxin type A
In use in the US since 2019.
Letybo
20 units for frown lines
A few small shots across the frown area. How many depends on how your injector maps your muscles.
Jeuveau
20 units for frown lines
The same dose, given the same way.
Letybo
Placebo, in three trials
Success rates ran from 47% to 65% across the three.
Jeuveau
Botox, head to head
Jeuveau did about as well as Botox at the same 20-unit dose. That is the strongest head-to-head evidence in this group.
Letybo
Entered as the lower-cost option
Jeuveau
Built on being the value option
Letybo
No home version
Letybo has to go into a muscle. The "Botox in a bottle" serums sold at drugstores sit on the surface of the skin. They cannot reach a muscle several millimetres down.
Jeuveau
No home version
The same is true of Jeuveau. Nothing sold over the counter puts a toxin into a muscle.
Letybo
Jeuveau
Letybo
Not really, and Letybo's own trials show why. The same product, at the same dose, produced success rates from 47% to 65% across its three trials. The drug did not change. What differed was who took part, and where.
Jeuveau
Jeuveau's trial is the exception. Botox and Jeuveau were tested in the same study at the same time, so that comparison is real. It just was not built to crown a winner.
Letybo
Letybo is letibotulinumtoxinA-wlbg, made by Hugel in South Korea. It was approved in the US in 2024 and launched in 2025. Jeuveau is prabotulinumtoxinA-xvfs, made by Evolus, and was approved in the US in 2019. Both are botulinum toxin type A in a protein complex of about 900 kDa. Units are brand-specific and are not interchangeable between brands.
Letybo's approval rested on three trials against placebo, about 1,270 people in total. Jeuveau's main trial included a Botox comparison group alongside a placebo group. Both routes are enough for FDA approval.
Common questions
Botulinum toxin can cause drooping or weakness. Seek urgent care for trouble swallowing or breathing. Discuss the specific product’s warnings with your injector.